Author

Mella I. Diaz

Observed names: M Díaz, Mella Diaz

Institution: MannKind Corporation (United States)

Observed institution: MannKind Corporation (United States)

OpenAlex ID: A5111633366

Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

2008 · Gabriela Senti, Bettina M. Prinz Vavricka, et al. · Proceedings of the National Academy of Sciences · 364

Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma

2008 · Jeffrey Weber, William Boswell, et al. · Journal of Immunotherapy · 83

Prospective safety study of immunotherapy administered in a cluster schedule.

2004 · P Serrano, J Algorta, et al. · PubMed · 14

Works count: 3

Citation count: 461

H-index: 3

I10-index: 3